P1163 ALL-ORAL THERAPY WITH DACLATASVIR IN COMBINATION WITH ASUNAPREVIR AND BMS-791325 FOR TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE 4 INFECTION
Tarek Hassanein, David Gardiner(Bristol-Myers Squibb (Germany)), Karen Sims(Bristol-Myers Squibb (Germany)), Lynn R. Webster(Adherent Technologies (United States)), Melanie E. Bennett(National Maternity Hospital), A. Griffies(Bristol-Myers Squibb (Germany)), Paul J. Thuluvath(University of Maryland, Baltimore), E. Läwitz, Bhaskar Rege(Bristol-Myers Squibb (Germany)), Zobair M. Younossi(Georgetown University), Nannan Zhou(Chinese Academy of Sciences), Fiona McPhee(Bristol-Myers Squibb (United States)), Megan Wind‐Rotolo(Bristol-Myers Squibb (United States)), Dennis M. Grasela(Bristol-Myers Squibb (United States)), Elizabeth Chung, Hongyu Zhou(Sichuan University), Howard Schwartz(Clinical Research Associates), Norman Gitlin(NYU Langone Health)
Cited by 12
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k